drugset / Trial / NCT02788747

Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

NCT02788747

Phase 2 Completed 71 enrolled Stealth BioTherapeutics Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).

Timeline

Start
2016-06
Primary completion
2017-09
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 4 mg Subcutaneous
Subject Elamipretide Peptide 40 mg Subcutaneous

Indications